Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations

Recent studies have indicated that afatinib is beneficial for patients with non‐small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor (EGFR) mutations, while the effectiveness of afatinib rechallenge has not been fully defined. Here, we report a long‐term survival case o...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Thorac Cancer
Huvudupphovsmän: Masuda, Tomomi, Sunaga, Noriaki, Kasahara, Norimitsu, Takehara, Kazutaka, Yatomi, Masakiyo, Hara, Kenichiro, Koga, Yasuhiko, Maeno, Toshitaka, Hisada, Takeshi
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley & Sons Australia, Ltd 2020
Ämnen:
Case Reports
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7396375/
https://ncbi.nlm.nih.gov/pubmed/32529804
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13532
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk